Lipid pharmacotherapy for treatment of atherosclerosis

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 8, 2014, Pages 1119-1125

  Nicholls, Stephen J ^a,b   Pisaniello, Anthony D ^a,b   Kataoka, Yu ^b   Puri, Rishi ^c  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Atherosclerosis; Lipids; Medical therapies; Risk factors

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOMITAPIDE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIPOMERSEN; NICOTINIC ACID; SUBTILISIN; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DYSLIPIDEMIA; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; HYPERTRIGLYCERIDEMIA; INFLAMMATION; MONOTHERAPY; PHARMACEUTICAL CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIMARY PREVENTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; ANIMAL; BLOOD; DYSLIPIDEMIAS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ATHEROSCLEROSIS; DYSLIPIDEMIAS; HUMANS; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; RISK FACTORS;

EID: 84900808960     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.904287     Document Type: Review

References (57)

1. Steinberg D, Gotto AM Jr. Preventing coronary artery disease by lowering cholesterol levels: fifty years from bench to bedside. JAMA 1999;282:2043-50
2. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 1996;335:1001-9
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the. Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1381-9
4. Shepherd J, Blauw GJ, Murphy MB, et al.; PROSPER study group; PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30
5. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet 2010;376:1670-81
6. Nissen SE, Tuzcu EM, Schoenhagen P, et al.; REVERSAL investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071-80
7. Kawasaki M, Sano K, Okubo M, et al. Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated back-scatter intravascular ultrasound. J Am Coll Cardiol 2005;45:1946-53
8. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID Trial. JAMA 2006;295:1556-65
9. Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011;365:2078-87
10. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29-38
11. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-65
12. Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin evaluation and infection therapy-Thrombolysis in Myocardial Infarction 22 investigators: intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504
13. Antman EM, Hand M, Armstrong PW, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008;51:210-47
14. Waters DD, Brotons C, Chiang CW, et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 2009;120:28-34
15. Bays HE, Moore PB, Drehobl MA, et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 2001;23:1209-30
16. Bayturan O, Kapadia S, Nicholls SJ, et al. Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol. J Am Coll Cardiol 2010;55:2736-42
17. Rader DJ, Kastelein JJ. Lomitapide and Mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with Homozygous familial hypercholesterolemia. Circulation 2014;129:1022-32
18. Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov 2012;11:367-83
19. Burnett JR, Hooper AJ. Common and rare gene variants affecting plasma LDL cholesterol. Clin Biochem Rev 2008;29:11-26
20. Blake GJ, Otvos JD, Rifai N, Ridker PM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 2002;106:1930-7
21. Botham KM, Moore EH, De Pascale C, et al. The induction of macrophage foam cell formation by chylomicron remnants. Biochem Soc Trans 2007;35:454-8
22. Miller M, Cannon CP, Murphy SA, et al.; PROVE IT-TIMI 22 Investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008;51:724-30
23. Kataoka Y, Uno K, Puri R, Nicholls SJ. ® Epanova and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy. Future Cardiol 2013;9:177-86 • Showing the efficacy and mechanism of Epanova, omega-3 fatty acids.
24. Anuurad E, Boffa MB, Koschinsky ML, Berglund L. Lipoprotein (a): a unique risk factor for cardiovascular disease. Clin Lab Med 2006;26:751-72
25. Bennet A, Di Angelantonio E, Erqou S, et al. Lipoprotein (a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med 2008;168:598-608
26. Suk Danik J, Rifai N, Buring JE, Ridker PM. Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA 2006;296:1363-70
27. AIM-HIGH Investigators, Boden WE, Probsfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-67
28. Tanis BC, van den Bosch MA, Kemmeren JM, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001;345:1787-93
29. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989;79:8-15
30. Gordon DJ, Rifkind BM. High-density lipoprotein-the clinical implications of recent studies. N Engl J Med 1989;321:1311-16
31. Nicholls SJ, Cutri B, Worthley SG, et al. Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 2005;25:2416-21
32. Cui Y, Watson DJ, Girman CJ, et al. Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study). Am J Cardiol 2009;104:829-34
33. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81
34. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-17
35. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005;45:185-97
36. The Results of HPS2-THRIVE study. Available from: www.thrivestudy.org
37. Angelin B, Parini P, Eriksson M. Reverse cholesterol transport in man: promotion of fecal steroid excretion by infusion of reconstituted HDL. Atheroscler Suppl 2002;3:23-30
38. Bisoendial RJ, Hovingh GK, Levels JHM, et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 2003;107:2944-8
39. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003;290:2292-300
40. Waksman R, Torguson R, Kent KM, et al. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol 2010;55:2727-35
41. Tardif JC, Gregoire J, L'Allier PL, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007;297:1675-82
42. Nicholls SJ, Gordon A, Johansson J, et al. Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial. J Am Coll Cardiol 2011;57:1111-19
43. Boekholdt SM, Kuivenhoven JA, Wareham NJ, et al. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study. Circulation 2004;110:1418-23
44. Okamoto H, Yonemori F, Wakitani K, et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000;406:203-7
45. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22
46. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356:1304-16
47. Nicholls SJ, Tuzcu EM, Brennan DM, et al. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation 2008;118:2506-14
48. Barter P. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Am J Cardiol 2009;104(Suppl):10E-5E
49. Vergeer M, Stroes ES. The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors. Am J Cardiol 2009;104(Suppl):32E- 8E
50. Schwartz GG, Olsson AG, Abt M, et al. dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367:2089-99
51. Cannon CP, Shah S, Dansky HM, et al.; Determining the Efficacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010;363:2406-15
52. Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011;306:2099-109
53. Ridker PM, Genest J, Boekholdt SM, et al.; JUPITER Trial Study Group. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet 2010;376:333-9
54. Tsai MY, Johnson C, Kao WH, et al. Cholesteryl ester transfer protein genetic polymorphisms, HDL cholesterol, and subclinical cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2008;200:359-67
55. Bhattacharyya T, Nicholls SJ, Topol EJ, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008;299:1265-76
56. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011;364:127-35
57. Nicholls SJ, Kastelein JJ, Schwartz GG, VISTA-16 Investigators. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA 2014;311:252-62